Země: Spojené státy
Jazyk: angličtina
Zdroj: NLM (National Library of Medicine)
FELBAMATE (UNII: X72RBB02N8) (FELBAMATE - UNII:X72RBB02N8)
Zydus Pharmaceuticals (USA) Inc.
FELBAMATE
FELBAMATE 400 mg
ORAL
PRESCRIPTION DRUG
Felbamate tablets, USP are not indicated as a first line antiepileptic treatment (see Warnings ). Felbamate tablets, USP are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgement, felbamate can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. Felbamate is contraindicated in patients with known hypersensitivity to felbamate, its ingredients, or known sensitivity to other carbamates. It should not be used in patients with a history of any blood dyscrasia or hepa
Felbamate Tablets USP, 400 mg are off-white to pale yellow colored, capsule shaped biconvex tablets, debossed with "10" and "53" separated by breakline on one side and plain on other and are supplied as: NDC 70710-1053-3 in bottles of 30 tablets NDC 70710-1053-9 in bottles of 90 tablets NDC 70710-1053-1 in bottles of 100 tablets NDC 70710-1053-5 in bottles of 500 tablets NDC 70710-1053-4 in cartons of 100 tablets (10 x 10 unit-dose) Felbamate Tablets USP, 600 mg are light pink to pink colored, capsule shaped biconvex tablets debossed with "10" and "54" separated by breakline on one side and plain on other and are supplied as: NDC 70710-1054-3 in bottles of 30 tablets NDC 70710-1054-9 in bottles of 90 tablets NDC 70710-1054-1 in bottles of 100 tablets NDC 70710-1054-8 in bottles of 180 tablets NDC 70710-1054-5 in bottles of 500 tablets NDC 70710-1054-4 in cartons of 100 tablets (10 x 10 unit-dose) Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in tight container. Manufactured by: Cadila Healthcare Limited Matoda, Ahmedabad, India. Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534 Rev.: 06/17
Abbreviated New Drug Application
FELBAMATE- FELBAMATE TABLET ZYDUS PHARMACEUTICALS (USA) INC. ---------- FELBAMATE TABLETS, USP BEFORE PRESCRIBING FELBAMATE TABLETS, THE PHYSICIAN SHOULD BE THOROUGHLY FAMILIAR WITH THE DETAILS OF THIS PRESCRIBING INFORMATION. FELBAMATE SHOULD NOT BE USED BY PATIENTS UNTIL THERE HAS BEEN A COMPLETE DISCUSSION OF THE RISKS AND THE PATIENT, PARENT, OR GUARDIAN HAS BEEN PROVIDED THE FELBAMATE WRITTEN ACKNOWLEDGEMENT (SEE PATIENT/PHYSICIAN ACKNOWLEDGEMENT FORM). WARNING: 1. APLASTIC ANEMIA THE USE OF FELBAMATE IS ASSOCIATED WITH A MARKED INCREASE IN THE INCIDENCE OF APLASTIC ANEMIA. ACCORDINGLY, FELBAMATE SHOULD ONLY BE USED IN PATIENTS WHOSE EPILEPSY IS SO SEVERE THAT THE RISK OF APLASTIC ANEMIA IS DEEMED ACCEPTABLE IN LIGHT OF THE BENEFITS CONFERRED BY ITS USE (SEE INDICATIONS). ORDINARILY, A PATIENT SHOULD NOT BE PLACED ON AND/OR CONTINUED ON FELBAMATE WITHOUT CONSIDERATION OF APPROPRIATE EXPERT HEMATOLOGIC CONSULTATION. AMONG FELBAMATE TREATED PATIENTS, APLASTIC ANEMIA (PANCYTOPENIA IN THE PRESENCE OF A BONE MARROW LARGELY DEPLETED OF HEMATOPOIETIC PRECURSORS) OCCURS AT AN INCIDENCE THAT MAY BE MORE THAN A 100 FOLD GREATER THAN THAT SEEN IN THE UNTREATED POPULATION (I.E., 2 TO 5 PER MILLION PERSONS PER YEAR). THE RISK OF DEATH IN PATIENTS WITH APLASTIC ANEMIA GENERALLY VARIES AS A FUNCTION OF ITS SEVERITY AND ETIOLOGY; CURRENT ESTIMATES OF THE OVERALL CASE FATALITY RATE ARE IN THE RANGE OF 20 TO 30%, BUT RATES AS HIGH AS 70% HAVE BEEN REPORTED IN THE PAST. THERE ARE TOO FEW FELBAMATE ASSOCIATED CASES, AND TOO LITTLE KNOWN ABOUT THEM TO PROVIDE A RELIABLE ESTIMATE OF THE SYNDROME'S INCIDENCE OR ITS CASE FATALITY RATE OR TO IDENTIFY THE FACTORS, IF ANY, THAT MIGHT CONCEIVABLY BE USED TO PREDICT WHO IS AT GREATER OR LESSER RISK. IN MANAGING PATIENTS ON FELBAMATE, IT SHOULD BE BORNE IN MIND THAT THE CLINICAL MANIFESTATION OF APLASTIC ANEMIA MAY NOT BE SEEN UNTIL AFTER A PATIENT HAS BEEN ON FELBAMATE FOR SEVERAL MONTHS (E.G., ONSET OF APLASTIC ANEMIA AMONG FELBAMATE- EXPOSED PATIENTS FOR WHOM DATA ARE AVAILABLE HAS RA Přečtěte si celý dokument